

Poly Medicure Limited

Regd. Office : 232-B, 3rd Floor, Okhla Industrial Estate,
Phase-III, New Delhi - 110020 (INDIA)
T: +91-11-33550700, 47317000, F: +91-11-26321894, 26321839
E: info@polymedicure.com W: polymedicure.com
CIN: L 40300DL1995PLC066923



Date: 22nd May, 2020

Scrip Code:- 531768

**The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services,
Phirozee Jeejeebhoy Towers,
Dalal Street, Mumbai- 400001.**

Scrip Code:- POLYMED

**The Manager
National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1-Block G,
Bandra Kurla Complex, Bandra(E),
Mumbai-400051.**

Subject: - Disclosure of material impact of CoVID-19 pandemic on Company

Ref: Intimation under Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated 20th May, 2020, we would like to inform you that the Company's main business is manufacturing of medical devices, which comes under the essentials services as per ministry of Home Affairs Order No. 40-3/2020-DM-I(A) dated 24th March, 2020 and which were exempted from lockdown.

The Company has also taken extensive steps to ensure the safety and welfare of its employees at its plants and offices.

There is no major adverse impact of COVID-19 on the Company's business operations.

Also, As per Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated 20th May, 2020; we are evaluating the impact of the CoVID-19 pandemic on business, performance and financials, both qualitatively and quantitatively, to the extent possible and will disseminate the same in due course.

Kindly take the above information on record.

Thanking you,
Yours faithfully,

For Poly Medicure Limited



**Avinash Chandra
Company Secretary**